From: MET in glioma: signaling pathways and targeted therapies
Agent | Oral, Intravenous | Molecular type | Mechanisms of Action | Animal model (Subcutaneous, Intracranial) | Clinical trail | Ref. |
---|---|---|---|---|---|---|
YYB-101 | Intravenous | A humanized monoclonal anti-HGF antibody | Neutralize HGF | Intracranial | NCT02499224 (Phase I) | |
Rilotumumab (AMG102) | Intravenous | A neutralizing antibody against HGF | Neutralize HGF | – | NCT01113398 (phase II) | |
Onartuzumab | Intravenous | A humanized monovalent monoclonal antibody | Block c-Met receptor | Intracranial (infused intratumorally using osmotic minipumps) | NCT01632228 (phase II) | |
Crizotinib | Oral | A tyrosine kinase inhibitor | Target ALK, ROS1, and MET | – | NCT02270034 (phase I) NCT01644773 (phase I) | |
Volitinib | Oral | A kinase inhibitor | Inhibit the phosphorylation of c-Met. | Subcutaneous | – | [88] |
SGX523 | Oral | Small molecule kinase inhibitor | Inhibite c-Met activation | Intracranial | NCT00607399 (phase I), NCT00606879 (phase I) | [89] |
INCB28060 | Oral | A novel inhibitor of c-MET kinase | Inhibit c-MET enzyme activity | Subcutaneous | – | [75] |
Cabozantinib (XL184) | Oral | A molecular kinase inhibitor | Inhibit VEGF receptor 2 (VEGFR2) and MET. | Intracranial | NCT00704288 (phase II) | |
Altiratinib | Oral | A kinase inhibitor | Inhibit the activation of MET, TIE2, VEGFR2, and tropomyosin receptor kinase family kinases. | Intracranial | – | [95] |
CM-118 | Oral | A novel lead compound | Selectivity inhibit the phosphorylation of c-Met and ALK. | Intracranial | – | [96] |
Brefelamide | – | An aromatic amide that was originally isolated from Dictyostelium cellular slime molds. | Inhibit the secretion of HGF and expression and activation of c-Met. | – | – | [97] |
PLB-1001 | Oral | A MET kinase inhibitor | High selectively inhibit the activation of Met | Subcutaneous and intracranial | NCT02978261 (Phase I) | [20] |